Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls (NCT05880862) | Clinical Trial Compass
Active — Not RecruitingEarly Phase 1
Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls
United States48 participantsStarted 2023-09-28
Plain-language summary
The goal of this study is to conduct a randomized pilot multi-arm clinical trial comparing a standard course of physical therapist provided pelvic floor muscle training (PFMT) to pharmacologic therapy for the treatment of urgency urinary incontinence (UUI) or Overactive Bladder (OAB) in older women at high risk of falling.
The central hypotheses for this project are i) a randomized pilot multi-arm clinical trial comparing PFMT to drug treatment for UUI or OAB in older women at high risk of falling is feasible; and ii) treatment approach can influence both UI and fall related outcomes in this patient population.
The main questions it aims to answer are: 1) Is a multi-arm clinical trial comparing PFMT to drug treatment for UUI or OAB in older women at high risk of falling feasible? and 2) How does treatment approach influence both OAB and fall related outcomes in this patient population?
Women (16 per arm) 60 years and older with UUI or OAB who screen positive for high fall risk will be randomized to one of three standard of care treatment arms and followed for six months. The three treatment arms are i) a 12-week structured behaviorally based pelvic floor muscle training (PFMT) intervention administered by physical therapists in the outpatient physical therapy clinic; ii) a 12-week course of the beta-3 agonist, Mirabegron; and iii) a 12-week course of the antimuscarinic, Trospium Chloride. Researchers will compare study feasibility and OAB symptom related outcomes across the three groups to see if a larger clinical trial is warranted.
Who can participate
Age range60 Years – 99 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Women aged 60 year or older.
✓. Ambulatory (able to walk across a small room with or without an assistive device).
✓. Urgency UI, OAB, or Mixed UI (both urgency and stress UI) as identified by study physicians.
✓. Answered "yes" to one of the items on the 3-Key Questions, questionnaire.
✓. A score of 6 or greater on the International Consultation on Incontinence Modular Questionnaire - Overactive Bladder (ICIQ-OAB) instrument or a physician recommended treatment.
✓. Able to provide one's own informed consent.
✓. Has tried basic lifestyle modifications for her bladder condition.
✓. Has Medicare or private insurance
Exclusion criteria
✕. Male (their causes of urinary incontinence are often different from women)
✕
What they're measuring
1
Evaluability
Timeframe: Assessed at the end of the 12-week intervention period
2
Clinical-Based Adherence
Timeframe: Assessed at the end of the 12-week intervention period
3
Home-Based Adherence
Timeframe: Assessed at the end of the 12-week intervention period
4
Medication Adherence
Timeframe: Assessed at the end of the 12-week intervention period
Trial details
NCT IDNCT05880862
SponsorThe University of Texas Medical Branch, Galveston
. Unstable psychiatric conditions (e.g., psychosis, suicidal) based on history and medical records.
✕. Nursing home resident
✕. Genitourinary cancer undergoing active treatment with chemotherapy or radiation.
✕. Neurologic conditions known to contribute to incontinence (Multiple Sclerosis, Parkinson's Disease, Traumatic Brain Injury, Dementia, and Stroke Survivors with limited mobility)
✕. New OAB treatments planned during the 6-month study duration - includes medications and/or surgery.
✕. History of surgically implanted sacral nerve stimulator or botulinum toxin bladder injections for UI.